tiprankstipranks
Crispr Therapeutics price target lowered to $55 from $59 at Barclays
PremiumThe FlyCrispr Therapeutics price target lowered to $55 from $59 at Barclays
17d ago
CRISPR Therapeutics Advances with Solid Financials and Approvals
Premium
Company Announcements
CRISPR Therapeutics Advances with Solid Financials and Approvals
17d ago
Crispr Therapeutics reports Q3 EPS ($1.01), consensus ($1.42)
Premium
The Fly
Crispr Therapeutics reports Q3 EPS ($1.01), consensus ($1.42)
17d ago
Cathie Wood’s ARK Investment bought 34K shares of Crispr Therapeutics today
PremiumThe FlyCathie Wood’s ARK Investment bought 34K shares of Crispr Therapeutics today
1M ago
AstraZeneca, CSPC deal shows Lp(a) space remains hot, says BMO Capital
Premium
The Fly
AstraZeneca, CSPC deal shows Lp(a) space remains hot, says BMO Capital
2M ago
CRISPR Therapeutics Deserves its Lofty Valuation Even with Conservative Forecasts
Premium
Market News
CRISPR Therapeutics Deserves its Lofty Valuation Even with Conservative Forecasts
2M ago
Oruka announces closing of merger with ARCA Biopharma
PremiumThe FlyOruka announces closing of merger with ARCA Biopharma
3M ago
Crispr Therapeutics call volume above normal and directionally bullish
Premium
The Fly
Crispr Therapeutics call volume above normal and directionally bullish
3M ago
Crispr Therapeutics price target lowered to $100 from $120 at Truist
Premium
The Fly
Crispr Therapeutics price target lowered to $100 from $120 at Truist
3M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100